Brief: PAION To Submit New Drug Application For Remimazolam In South Korea
30/12/2019 09:15
Dec 30 (Reuters) - PAION AG PA8G.DE :
* ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR
REMIMAZOLAM BY
ITS LICENSEE HANA PHARM IN SOUTH KOREA
Source text for Eikon: ID:nEQ5H60Lba
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022